Gert Ossenkoppele is Professor of Hematology at the VU University Medical Center in Amsterdam, The Netherlands, a position he has held since 2003. He obtained his doctorate of medicine at that same university in 1977. His PhD thesis (in 1990) was entitled ‘Differentiation induction in AML’. Professor Ossenkoppele has authored over 380 publications in peer-reviewed journals. His research interest is mainly translational and includes studies of (stem cell) biology, immunotherapy, and minimal residual disease (MRD) detection to direct treatment approaches for myeloid malignancies [acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS)]. He is principal investigator of several clinical AML trials and a past board member of the Dutch Society of Hematology. He is a member of the executive board of HOVON (Dutch–Belgian Hematology Trial Group). In addition, he chairs the AML Working Party of HOVON and is a lead participant of the AML Workpackage of the European LeukemiaNet (ELN), as well as a board member of the ELN Foundation. Professor Ossenkoppele recently stepped down from the board of the European Hematology Association (EHA). Furthermore, he chairs the AML Scientific Working Party of EHA and is recently appointed chair of the Educational of EHA. He is section editor of the European Journal of Hematology and reviewer for many high-ranking hematology journals.
You can see my upcoming and previous webinars here.